Randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculoneuropathy

Neurology

Volumn 53, Issue 1, 1999, Pages 57-61

  Hadden, R D M ^a,b   Sharrack, B ^a   Bensa, S ^a   Soudain, S E ^a   Hughes, R A C ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON;

ADULT; AGED; ARTICLE; AUTOIMMUNITY; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMYELINATING DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; INFLAMMATORY CELL; MALE; NERVE CONDUCTION; NEUROPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033551504     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.1.57     Document Type: Article

References (27)

1. Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, Groover RV. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 1975;50:621-651.
2. Prineas JW, McLeod JG. Chronic relapsing polyneuritis. J Neurol Sci 1976;27:427-458.
3. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48:321-328.
4. McCombe PA, Pollard JD, McLeod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. Brain 1987;110:1617-1630.
5. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy: clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-884.
6. Choudhary PP, Hughes RAC. Long-term treatment of chronic inflammatory demyelinating polyradiculoneuropathy with plasma exchange or intravenous immunoglobulin. QJM 1995; 88:493-502.
7. Hartung H-P, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome: part I. Muscle Nerve 1995;18:137-153.
8. Panitch HS. Interferons in multiple sclerosis. Drugs 1992;44: 946-962.
9. Arnason BGW. Interferon beta in multiple sclerosis. Neurology 1993;43:641-643.
10. De Luca G, Lugaresi A, Iarlori C, Marzoli F, Uncini A, Gambi D. Interferon beta normalizes suppressor cell function in dysimmune neuropathies. J Neuroimmunol 1998;82:1-4.
11. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
12. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
13. Rudick RA, Goodkin DE, Jacobs LD, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. Neurology 1997;49:358-363.
14. PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
15. Choudhary PP, Thompson N, Hughes RAC. Improvement following interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1995;242:252-253.
16. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for the diagnosis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Neurology 1991;41:617-618.
17. Kleyweg RP, Van der Meche FGA, Schmitz PIM. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14:1103-1109.
18. Goodkin DE, Hertsgaard D, Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil 1988;69:850-854.
19. Hauser SL, Dawson DM, Lehrich JR, et al. Intensive immunosuppression in progressive multiple sclerosis: a randomised three-arm study of high dose intravenous cyclophosphamide, plasma exchange and ACTH. N Engl J Med 1983;308:173-180.
20. Hall KM, Hamilton BB, Gordon WA, Zlaser ND. Characteristics of functional assessment indices: disability rating scale, function independence measure, and functional assessment measure. Journal of Head Trauma Rehabilitation 1993;8:60-74.
21. Scott OM, Hyde SA, Goddard C, Dubowitz V. Quantitation of muscle function in children: a prospective study in muscular dystrophy. Muscle Nerve 1982;5:291-301.
22. Sharrack B, Hughes RAC, Soudain S. Guy's Neurological Disability Scale. J Neurol 1996;243:S32. Abstract.
23. EuroQoL Group. A new facility for measurement of health related quality of life. Health Policy 1990;16:199-208.
24. Sabatelli M, Mignogna T, Lippi G, et al. Interferon-alpha may benefit steroid unresponsive chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1995; 58:638-639.
25. Gorson KC, Allam G, Simovic D, Ropper AH. Improvement following interferon-alpha 2a in chronic inflammatory demyelinating polyneuropathy. Neurology 1997;48:777-780.
26. Gorson KC, Ropper AH, Clark BD, Dew RB, Simovic D, Allam G. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology 1998;50:84-87.
27. Thompson N, Choudhary P, Hughes R, Quinlivan R. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996;243:280-285.